Retention and expansion for agencies: how to productise the offering for healthcare and life sciences

This edition is written for commercial leaders at healthtech, medtech, and life-sciences companies. In healthcare and life sciences, healthcare buyers move under regulatory constraint and reward domain-specific messaging, so the way you install retention and expansion has to reflect that reality from day one.

Retention and expansion is one of the highest-margin offerings an agency can add in 2026. It is keeping and growing the customers you already paid to acquire, and clients will pay a premium for the discipline they cannot install themselves.

Productise around outcome, not activity. Sell gross and net revenue retention moving to a defined level in a defined window, not a monthly retainer of vague ops.

Delivery pod: one strategist, one operator, one editor. Fewer people than that risks quality; more than that dilutes margin.

The binding constraint we see in healthcare and life sciences is almost always regulated-sale cycle length, not intent. Retention and expansion is only useful in this vertical when it is pointed at that constraint — not at a generic growth number borrowed from another category.

Onboarding takes two weeks: diagnosis, list build, trigger definition, kill criteria. Do not ship anything live before the diagnosis is signed off.

Pricing: outcome-linked base plus a monthly ops fee. The base rewards results; the ops fee funds the delivery pod.

Client failure mode: treating CS as a support cost centre. Write it into the engagement letter as a shared risk, not something you absorb quietly.

The agencies making the most from retention and expansion are the ones with the tightest playbook. Documented, versioned, and improved every quarter.

Concretely for healthcare and life sciences: the healthcare teams that install this get past procurement instead of dying in it. That is the reason it is worth installing retention and expansion properly rather than half-heartedly across three vendors.